Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

New-onset atrial fibrillation after surgical aortic valve replacement and transcatheter aortic valve implantation: a concise review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. State of Transcatheter Aortic Valve Implantation in Spain Versus Europe and Non-European Countries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Catheter Ablation of Focal Atrial Tachycardia Using Remote Magnetic Navigation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Comparison of the novel vasodilator uridine triphosphate and adenosine for the measurement of fractional flow reserve

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reevaluation of the indications for permanent pacemaker implantation after transcatheter aortic valve implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. 2020 ESC Guidelines for the management of adult congenital heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reply to: TFC ECG in arrhythmogenic cardiomyopathy: Inadequate mixture of criteria?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

Surgical aortic valve replacement (SAVR) and, more recently, transcatheter aortic valve implantation (TAVI) have been shown to be the only treatments that can improve the natural cause of severe aortic valve stenosis. However, after SAVR and TAVI, the incidence of new-onset atrial fibrillation (NOAF) is 31%-64% and 4%-32%, respectively. NOAF is independently associated with adverse events such as stroke, death, and increased length of hospital stay. Increasing the knowledge of predisposing factors, optimal postprocedural monitoring, and prophylactic antiarrhythmic and antithrombotic therapy may reduce the risk of complications secondary to NOAF.

OriginalsprogEngelsk
TidsskriftThe Journal of invasive cardiology
Vol/bind27
Udgave nummer1
Sider (fra-til)41-7
Antal sider7
ISSN1042-3931
StatusUdgivet - jan. 2015

ID: 46182191